$16.22
2.41% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
US0042251084
Symbol
ACAD
Sector
Industry

ACADIA Pharmaceuticals Inc. Stock price

$16.62
-1.54 8.48% 1M
+1.49 9.85% 6M
-1.73 9.43% YTD
-1.49 8.23% 1Y
-9.60 36.61% 3Y
-25.06 60.12% 5Y
-14.87 47.22% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.30 1.84%
ISIN
US0042251084
Symbol
ACAD
Sector
Industry

Key metrics

Market capitalization $2.77b
Enterprise Value $2.07b
P/E (TTM) P/E ratio 12.22
EV/FCF (TTM) EV/FCF 13.16
EV/Sales (TTM) EV/Sales 2.16
P/S ratio (TTM) P/S ratio 2.89
P/B ratio (TTM) P/B ratio 3.78
Revenue growth (TTM) Revenue growth 31.85%
Revenue (TTM) Revenue $957.80m
EBIT (operating result TTM) EBIT $84.28m
Free Cash Flow (TTM) Free Cash Flow $157.20m
Cash position $755.99m
EPS (TTM) EPS $1.36
P/E forward 30.46
P/S forward 2.61
EV/Sales forward 1.95
Short interest 11.67%
Show more

Is ACADIA Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

ACADIA Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:

12x Buy
60%
7x Hold
35%
1x Sell
5%

Analyst Opinions

20 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:

Buy
60%
Hold
35%
Sell
5%

Financial data from ACADIA Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
958 958
32% 32%
100%
- Direct Costs 82 82
97% 97%
9%
876 876
28% 28%
91%
- Selling and Administrative Expenses 473 473
18% 18%
49%
- Research and Development Expense 303 303
14% 14%
32%
100 100
248% 248%
10%
- Depreciation and Amortization 16 16
184% 184%
2%
EBIT (Operating Income) EBIT 84 84
215% 215%
9%
Net Profit 226 226
469% 469%
24%

In millions USD.

Don't miss a Thing! We will send you all news about ACADIA Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ACADIA Pharmaceuticals Inc. Stock News

Neutral
Business Wire
20 days ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 5, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 71,981 shares of common stock and 42,159 restricted stock units (“RSUs”) to thirteen new employees under Acadia's 2024 Inducement P...
Neutral
Business Wire
21 days ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences: UBS Virtual CNS Day 2025 Fireside Chat: Monday, March 17, 2025 at 11:00 a.m. Eastern Time Stifel 2025 Virtual CNS Forum Fireside Chat: Wednesday, March 19, 2025 at 12:30 p.m. Eastern Time 24th Annual Needham Virtual Healthcare Conference ...
Neutral
Business Wire
29 days ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability and exploratory efficacy of DAYBUE® (trofinetide) in girls ages two to four living with Rett syndrome (n = 15). The long-term Phase 2/3 study demonstrated DAYBUE had a similar safety profile in chi...
More ACADIA Pharmaceuticals Inc. News

Company Profile

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Head office United States
CEO Catherine Adams
Employees 654
Founded 1993
Website www.acadia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today